Globe

Executive Committee

Executive Committee Members

Alan Aubrey

Chief Executive Officer

Alan Aubrey

Chief Executive Officer

Alan was the joint founder and Chief Executive of Techtran Group Ltd, the first company in Europe to offer a complete outsourced technology transfer function to universities. Techtran was acquired by IP Group in 2005. From 1995-2002 Alan was a partner in KPMG where he specialised in providing advice to fast growing technology businesses. Alan holds a BA in Economics from the University of Leeds, an MBA with Distinction from the University of Bradford and is a fellow of the Institute of Chartered Accountants of England and Wales. Alan is also Non-Executive Chairman of Proactis Holdings plc, an AIM-listed software company based in York, and Non-executive Director of Oxford Sciences Innovation plc.

Angela Leach

General Counsel & Company Secretary

Angela Leach

General Counsel & Company Secretary

In addition to providing legal services at group level and co-ordinating external legal requirements, Angela also provides ad hoc legal support to IP Group’s portfolio of spin-out companies created amongst its ten university partners. Angela trained and qualified at leading London law firm CMS Cameron McKenna and spent two years post qualification in the corporate department before moving to AIM specialist Memery Crystal where she advised a number of technology companies on their AIM listings. Angela, who joined IP Group in January 2007, specialises in all aspects of corporate and commercial law, along with intellectual property law, having obtained a Postgraduate Diploma in Commercial Intellectual Property Law with distinction from Nottingham Law School in June 2006.

David Baynes

Chief Operating Officer

David Baynes

Chief Operating Officer

David was appointed to the Board in March 2014 following the acquisition of Fusion IP plc, where he was Chief Executive Officer and one of the founders. David had been a board director of Fusion IP plc since 2004, having been a director of Fusion IP Trading since 2003. Previously, David worked at Celsis International plc from its incorporation to its flotation on the full list of the London Stock Exchange in July 1993; Toad plc (now 21st Century Technology PLC), which he also co-founded where he was responsible for taking the company from start-up to a full listing on the London Stock Exchange. David was also CFO of Codemasters Limited, the UK's largest privately held games company.

Dr Alison Fielding

Director, IP Impact

Dr Alison Fielding

Director, IP Impact

Ali co-founded Techtran Group Ltd and was the Chief Operating Officer of Techtran when it was acquired by IP Group in January 2005. She was a director of IP Group until July 2013 when she moved into a new role with the Company as Director of IP Impact. Previously, Ali spent five years at McKinsey & Co where she consulted primarily to the pharmaceutical and health care sectors. Prior to McKinsey, Ali spent four years as a development chemist for Zeneca, performing technical roles in the speciality chemicals and agrochemicals divisions. Ali holds an MBA from Manchester Business School, a Ph.D. in Organic Chemistry and a first class degree in Chemistry from the University of Glasgow. Ali is a trustee of Care International UK, one of the world’s three biggest aid agencies working with 82m people in 87 countries.

Dr Sam Williams

Head, Biotech

Dr Sam Williams

Head, Biotech

Sam has 18 years' experience in the biotechnology industry, both as a top-ranked equity analyst in the City and, subsequently, as an entrepreneur and Chief Executive. From 2002 to 2007 he worked at Lehman Brothers where he was ranked the number one European biotechnology equity analyst by Institutional Investor magazine three years in a row, before becoming Industry Group Leader for Pharmaceuticals and Chemicals. Sam left Lehman Brothers in 2007 to establish Modern Biosciences (MBS), an IP Group Plc portfolio company focused on the development of novel treatments for chronic, inflammatory diseases. MBS’ lead drug for rheumatoid arthritis is currently in Phase 1 studies and is the subject of a £176m Option and Licensing deal with Janssen Biotech Inc. (J&J), signed in November 2014. As well as being CEO of MBS, Sam oversees IP Group's portfolio of biotechnology investments. He is a board member of the UK BioIndustry Association (BIA) and a non-executive director of C4X Discovery Holdings Plc. Sam has a PhD from Cambridge University and an MA in Pure and Applied Biology from Oxford University.

Greg Smith

Chief Financial Officer

Greg Smith

Chief Financial Officer

Greg joined IP Group as Group Financial Controller in January 2008 and was appointed Chief Financial Officer in June 2011. Prior to IP Group, Greg worked at Tarchon Capital Management, a multi-billion dollar fund of hedge funds business where he built and managed the operations and accounting team and the operational due diligence process for investee hedge funds. Greg originally trained as an accountant in KPMG’s London Financial Services practice working with asset management, insurance and banking clients. Greg is a Fellow of the ICAEW and holds a degree in Mathematics from the University of Warwick.

Mike Townend

Chief Investment Officer

Mike Townend

Chief Investment Officer

Mike joined IP Group's Board in 2007 from Lehman Brothers where he was Managing Director of European Equities and Head of Equity Sales to Hedge Funds. He has 17 years experience in all aspects of equity capital markets and the investment process and was also a key member of the senior relationship management programme at Lehman Brothers. Prior to this, he was an Executive Director at Donaldson, Lufkin and Jenrette with responsibility for building the bank’s business with hedge funds and alternatives. Mike has sourced, co-led or led numerous private and public transactions. He is the IP Group representative on the boards of Modern Water plc, Revolymer plc and Applied Graphene Materials plc. He is also a non-executive director of Green Urban Transport Ltd.

Peter Grant

Managing Director, New Business & Partnerships

Peter Grant

Managing Director, New Business & Partnerships

Peter heads up the Group's New Business & Partnerships division. He joined IP Group in March 2014 following the acquisition of Fusion IP plc, where he was Co-Founder and Operations Director. Peter has a PhD in Biochemistry from Cardiff University and has previously worked at Genzyme UK Limited; Celltech Limited; Enzymatix Limited and Celsis plc, which he co-founded and took to a full listing on the London Stock Exchange. He was appointed to the Board of Fusion IP plc on 1 December 2004, having been a director of Fusion IP Trading since 2 January 2003.